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INTRODUCTION
Tyrosine kinase inhibitors (TKIs) of epidermal growth 
factor receptor (EGFR) can be considered the standard first-
line therapy of patients with advanced non–small-cell lung 
cancer (NSCLC) harboring activating EGFR mutations. 
Despite an initial response to TKIs, the development of sec-
ondary resistance leads to treatment failure.1 Various mech-
anisms have been reported to be associated with acquired 
resistance to EGFR–TKIs, including the presence of the 
exon 20 T790M mutation that produces resistance to TKIs 
by increasing the affinity of the EGFR to ATP.2,3 Therefore, 
patients harboring the exon 20 T790M mutation are generally 
considered to be resistant to reversible TKIs (gefitinib or erlo-
tinib).4 We report a case of a long-lasting response to gefitinib 
in an advanced NSCLC patient, harboring both an activating 
and a “resistance” EGFR mutation.
CASE REPORT
On June 1, 2010 a 72-year-old man, formerly a light 
smoker, was admitted to our institution for a lung lesion of 
the left lower lobe, with mediastinal lymph nodes, and lung, 
hepatic, and bone metastases (Fig. 1A). The Eastern Cooperative 
Oncology Group performance status was 2. A liver biopsy was 
positive for a large-cell carcinoma, TTF-1 and CK-7 positive. 
EGFR mutational analysis performed by polymerase chain reac-
tion/sequencing and the Qiagen Therascreen EGFR Mutations 
Kit (Qiagen, Milan, Italy) showed three different mutations in the 
tumor, as confirmed by two independent analyses: c.2236–2250 
deletion in the exon 19, producing the aminoacidic deletion 
p.E746-A750; c.2369C>T mutation in exon 20 (p.T790M); 
c.2573T>G (p.L858R) point mutation in exon 21. The differ-
ence in threshold cycle between the control and the mutation-
specific assays (∆Ct) suggested that the three mutations were 
not equally represented in the tumor, and that alleles carrying 
the c.2236–2250 deletion (∆Ct 0.31) were more abundant as 
compared with the T790M mutation (∆Ct 3.28), with the L858R 
showing the lowest levels of mutant alleles (∆Ct 5.90) (Fig. 2). 
On these bases, on August 11, 2010, the patient was started on 
therapy with gefitinib 250 mg/day, after completing radiotherapy 
on bone sites. On September 20, 2010, a partial response to 
gefitinib was observed, with a reduction of the left lung lesion, 
hepatic metastases, and disappearance of the bilateral lung nod-
ules (Fig. 1B). The treatment was continued without significant 
toxicity until April 30, 2011, when a lung and liver progression 
of disease was observed. Gefitinib was stopped and the patient 
was switched to gemcitabine as single agent for six cycles.
DISCUSSION
It has been demonstrated using highly sensitive tech-
niques that up to 35% of NSCLC patients with an activat-
ing EGFR mutation also carry clones of tumor cells with the 
T790M mutation, which is not detectable using routine diagnos-
tic tests.5 Our patient showed a peculiar mutational profile, with 
three different mutations, but the T790M mutation was pres-
ent only in a fraction of cells harboring sensitizing mutations, 
explaining the long response to gefitinib (8 months). Therefore, 
the presence of a T790M mutation with an activating EGFR 
mutation should not be considered as a contraindication to first-
line therapy with TKIs in advanced NSCLC patients. Our data 
also suggest that relative quantification of mutant alleles might 
provide information useful for treatment decision.
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FIGURE 1.  Computed tomography scan (A) at 
diagnosis and (B) after 1 month of therapy with 
gefitinib.
FIGURE 2.  Analysis of EGFR mutations with the 
Qiagen Therascreen EGFR Mutations kit. EGFR, epi-
dermal growth factor receptor.
